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RESUMO
Objectivos: A prevalência de Sindroma Metabólica (SM) e diabetes é variável consoante a definição utilizada, assim como com a 
região geográfica e o grupo étnico estudado. Não existem estudos em indivíduos portugueses com suspeita de doença arterial coro-
nária. Analisámos a prevalência de SM e diabetes nesta população específica de doentes, comparando também definições.
Métodos: Incluíram-se no estudo 300 indivíduos, com uma idade media de 64 ± 9 anos, 59% do género masculino, admitidos para 
angiografia coronária electiva, tendo sido excluídos os doentes com doença cardíaca previamente conhecida. Avaliou-se a prevalência 
de SM e de diabetes.
Resultados: A prevalência ajustada de SM foi de 39,3% (critério NCEP-ATP III), 53,8% (critério IDF) e 48,4% (critério AHA/NHLBI). A 
prevalência ajustada de diabetes foi de 14,8% pela definição prévia da ADA e de 36.4% com a definição mais recente. A concordância 
global entre as definições de SM foi de 45,3%, sendo mais elevada entre as definições da AHA/NHLBI e da NCEP-ATP III (Kappa 
0,821). A prevalência de SM está altamente dependente da idade em ambos os géneros, sendo mais prevalente no género feminino. 
A prevalência de diabetes é também dependente da idade, sendo semelhante em ambos os géneros. O componente de SM mais 
frequente é a hipertensão arterial, seguido pela obesidade abdominal, elevação da glicose, colesterol-HDL baixo e finalmente elevação 
dos triglicéridos. É também importante referir que 60% dos doentes estavam sob terapêutica hipolipemiante (56,6% com estatinas, 
1,7% com fibratos e 1,7% com ambos). A diferença mais significativa entre géneros no que diz respeito aos componentes de SM é a 
elevada prevalência de obesidade abdominal no género feminino.
Conclusões: Nesta população de alto risco, a prevalência de SM é elevada, sendo contudo a prevalência de diabetes semelhante à 
registada em estudos epidemiológicos na população geral.  
AbStRACt
Objectives: Metabolic syndrome and diabetes prevalence varies according to chosen definition, as well as with the geographical and 
ethnical group. No studies are available in Portuguese patients with suspected coronary artery disease. We analysed metabolic syn-
drome and diabetes prevalence in this specific population and compared definitions.
Methods: The study included 300 patients, with a mean age of 64 ± 9 years, 59% males, admitted for an elective coronary angiography 
and we excluded patients with previous cardiac disease. Metabolic syndrome and diabetes prevalence was obtained.
Results: The adjusted prevalence of metabolic syndrome was found to be 39.3% (NCEP-ATP III criteria), 53.8% (IDF criteria) and 
48.4% (AHA/NHLBI). Adjusted prevalence of diabetes was 14.8% by the previous ADA definition and 36.4% with the new definition. 
Global agreement between metabolic syndrome definitions was 45.3%, with the highest value between AHA/NHLBI and NCEP-ATP III 
(Kappa 0.821). Metabolic syndrome prevalence was highly age-dependent in both genders and more prevalent in females. Diabetes 
prevalence was also age-dependent, with similar prevalence in both genders. The most frequent metabolic syndrome component was 
hypertension, followed by abdominal obesity, raised glucose, low HDL-cholesterol and finally increased triglycerides. It is also important 
to mention that 60% of the patients were under lipid-lowering treatment (56.6% with statins, 1.7% with fibrates and 1.7% with both). 
The most significant difference between genders for metabolic syndrome components is the high prevalence of abdominal obesity in 
females.
Conclusions: In this high-risk population, metabolic syndrome prevalence is high, with similar diabetes prevalence compared with 
general population epidemiological studies.
INtRODUCtION
 Metabolic syndrome (MS) is a cluster of metabolic dis-
turbances that includes abdominal obesity, atherogenic 
dyslipidemia (hypertriglyceridemia and/or low HDL-choles-
terol), elevated blood pressure, and glucose metabolism 
disorders, and is a determinant of cardiovascular disease 
and type 2 diabetes.1,2 Cardiovascular disease is a major 
problem in Portugal, not only as far as coronary artery dis-
ease is concerned, but also in terms of stroke, the incidence 
of which is among the highest in the world.3 Clinically it is 
of great significance the identification of patients at risk of 
developing cardiovascular disease and/or diabetes to en-
able preventive interventions and promote lifestyle modi- 
fications. In the last few years, there have been several 
definitions and classification criteria for MS. Currently, the 
definitions most often used for MS are those of the National 
Cholesterol Education Program – Third Adult Treatment 
Panel (NCEP-ATP III), the International Diabetes Federa-
tion (IDF) and a more recent definition from the American 
Heart Association and the National Heart, Lung, and Blood 
Institute (AHA/NHLBI).4-6
 Since there is a strong age and gender dependence in 
the prevalence of MS and diabetes, as well as a geographi-
cal variation, it is important to perform specific studies in 
regional populations.7,8 In Portugal, there are few studies in 
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the general population, but no study addressed specifically 
the high-risk population with suspected coronary artery dis-
ease.9-17 Other studies in similar populations performed in 
European countries used mainly NCEP-ATP III definition 
and no comparison was made with the more recent defi-
nition. Also the impact of the recent definition of diabetes 
from the American Diabetes Association (ADA) was not yet 
analysed in a Portuguese population.18
 In a sample of individuals admitted for an elective coro-
nary angiography with suspected coronary artery disease, 
we analysed the prevalence of MS using the new AHA/
NHLBI definition and compared it with the two older defini-
tions, measuring classification agreement. Diabetes preva-
lence was analysed with the 2003 ADA definition and com-
pared it with the most recent definition.18,19 In general, we 
aimed to characterize the cardiovascular risk profile of an 
adult Portuguese population with suspected coronary artery 
disease by determining the prevalence of diabetes, MS and 
each of its components.
MAtERIAL AND MEtHODS
 The present study is an observational and cross-sec-
tional study, with prospective inclusion of patients admitted 
for an elective coronary angiography with suspected coro-
nary artery disease (clinically or with ischemia documen-
tation by non-invasive tests) between 2008 and 2010. All 
patients had an age ≥ 18 years. Patients with previously 
known heart disease were excluded. All patients gave their 
written informed consent and the study protocol conforms to 
the ethical guidelines of the 1975 Declaration of Helsinki.
 Anthropometrical data were obtained after an overnight 
fast. Body weight was measured to the nearest kilogram, 
and height to the nearest centimetre. Body Mass Index 
(BMI) was calculated as weight in kilograms divided by the 
height in meters, squared. Waist circumference (WC) was 
measured to the nearest centimetre, with the subject stand-
ing, midway between the lower limit of the rib cage and the 
iliac crest. Obesity was defined as BMI ≥ 30 Kg/m2, over-
weight as BMI 25-29.9 Kg/m2, normal BMI as < 25 Kg/m2. 
Blood pressure was measured on several occasions during 
hospital stay and hypertension was defined by a previous 
diagnosis of hypertension or the presence of systolic blood 
pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 
mmHg (mean of two consecutive measurements). Patients 
that smoked during the previous six months were classi-
fied as smokers and were self-reported. Patients on treat-
ment with lipid-lowering drugs or with abnormal lipid profile 
were classified has having hyperlipidemia. All participants 
were asked to bring their current medication and this was 
recorded.
 A venous blood sample was drawn after a 12-hour 
overnight fast. Serum glucose, total cholesterol and triglyc-
erides were determined using automatic standard routine 
enzymatic methods. HDL-cholesterol was determined after 
specific precipitation. LDL-cholesterol was determined by 
Friedwald formula.
 MS was considered present by the NCEP-ATP III defi-
nition if at least three of the following characteristics were 
present: fasting glucose ≥ 110 mg/dL; blood pressure ≥ 
130/85 mmHg; triglycerides ≥ 150 mg/dL; HDL-cholesterol 
< 50 mg/dL in women and < 40 mg/dL in men; WC ≥ 88 cm 
in women and ≥ 102 cm in men.4 The IDF definition was 
WC³ 80 cm in women and³ 94 cm in men, and at least two 
of the following: fasting glucose ≥ 100 mg/dL or previously 
diagnosed type 2 diabetes; blood pressure ≥ 130/85 mmHg 
or antihypertensive medication; triglycerides ≥ 150 mg/dL or 
specific treatment for this lipid abnormality; HDL-cholesterol 
< 50 mg/dL in women and < 40 mg/dL in men or specific 
treatment for this lipid abnormality.5 Finally, the AHA/NHLBI 
defined MS as at least three of the following: fasting glucose 
≥ 100 mg/dL or antidiabetic treatment; blood pressure ≥ 
130/85 mmHg or antihypertensive medication; triglycerides 
≥ 150 mg/dL or specific treatment for this lipid abnormality; 
HDL-cholesterol < 50 mg/dL in women and < 40 mg/dL in 
men or specific treatment for this lipid abnormality; WC ≥ 88 
cm in women and ≥ 102 cm in men.6
 Diabetes was defined as a previous diagnosis or in the 
presence of a fasting glucose level ≥ 126 mg/dL according 
to 2003 ADA definition, or the above criteria and/or a gli-
cated hemoglobin ≥ 6.5% by the 2010 ADA definition.18,19
 Significant coronary artery disease was defined by a 
coronary stenosis ≥ 50% in any segment.
Statistical analysis
 Statistical analysis was performed with PASW version 
18 statistical software (Chicago, Illinois, USA). A p-value < 
0.05 was considered statistically significant.
 Continuous variables were described as mean and 
standard deviation, or as median values and corresponding 
25th and 75th percentiles for non-normally distributed vari-
ables. Comparison was made with Student’s t-test or Mann-
Whitney’s test as appropriate. One-way ANOVA or Kruskal-
Wallis’s test was used to compare continuous variables with 
more than two groups. Proportions were reported for cate-
gorical variables and compared using the chi-square test or 
Fischer’s exact test, whenever appropriate. Prevalence was 
adjusted for gender and age by the total probability theo-
rem, taking into account the demographical composition of 
the adult population resident in Portugal in 2000 (National 
Institute of Statistics data) to make results comparable to 
other general population studies. The kappa coefficient was 
used to analyse statistical agreement between metabolic 
syndrome definitions. 
RESULtS
 We included 300 patients in the study, with a mean age 
of 64 ± 9 years (aged 38 - 86 years), 59% males (Table 
1). In females, the prevalence of smoking was lower, but 
the prevalence of the other risk factors was similar between 
genders. Treatment was also identical, as well as almost all 
laboratorial parameters with the exception of HDL-choles-
terol and creatinine (Table 1). WC was similar but women 
had higher BMI. The combined prevalence of Obesity / 
Overweight in the present population reaches 80%.
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Table 1 – Characteristics of the study population and by gender.
Characteristics
total
Mean ± SD
Median (IQR)
%
Females
Mean ± SD
Median (IQR)
%
Males
Mean ± SD
Median (IQR)
%
p-value
Age (years) 64.4 ± 9.2 64.5 ± 9.2 64.4 ± 9.1 0.942
Risk factors (%)
     Hypertension 79 85 86 1.000
     Hyperlipidemia 70 73 67 0.331
     Smoking 9 1 15 <0.001
     Diabetes mellitus 23 24 23 0.953
treatment (%)
     Hypertension 79 80 78 0.832
     Diabetes 20 21 19 0.792
     Hyperlipidemia 60 60 60 1.000
Anthropometrical data
     Weight (Kg) 76.0 ± 12.1 72.4 ± 11.6 78.6 ± 11.9 <0.001
     Height (cm) 163.8 ± 8.4 158.3 ± 7.2 168.2 ± 7.2 <0.001
     BMI (Kg/m2) 28.4 ± 4.3 29.2 ± 4.8 27.8 ± 3.8 0.005
     Waist circumference (cm) 99.2 ± 12.6 99.2 ± 13.5 99.2 ± 12.0 0.975
bMI groups (%) 0.047
     Normal 20 17 23
     Overweight 50 46 53
     Obesity 30 37 24
Laboratorial data
     Glucose (mg/dL) 100 (92–115) 99 (92-111) 101 (93-117) 0.316
     Insulin (mU/mL) 8.6 (5.7–13.6) 8.9 (5.8-13.3) 8.3(5.7-13.8) 0.848
     HOMA index 2.3 (1.4–3.8) 2.4 (1.5-3.5) 2.2 (1.4-4.0) 0.808
     HbA1c (%) 6.4 (6.0–7.0) 6.5 (6.0-7.1) 6.3 (6.0-6.8) 0.127
     Total cholesterol (mg/dL) 181 (155–213) 181 (154-219) 180 (157-212) 0.510
     HDL-cholesterol (mg/dL) 43 (36–54) 48 (40-57) 41 (34-49) <0.001
     LDL-cholesterol (mg/dL) 114 (93–136) 113 (90-136) 114 (96-135) 0.741
     Triglycerides (mg/dL) 97 (68–134) 93 (62-125) 99 (71-137) 0.080
     Creatinine (mg/dL) 0.9 (0.8–1.0) 0.8 (0.7-0.9) 1.0 (0.8-1.1) <0.001
SD, standard deviation; IQR, interquartil range; BMI, body mass index; HOMA, Homeostasis Model Assessment; HbA1c, Glicated hemoglobin.
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 MS prevalence was 55.3% by the AHA/NHLBI definition, 
which was intermediate between the NCEP-ATP III and the 
IDF definition (Table 2). The prevalence was also higher 
in females in all definition. Agreement between MS defini-
tions was variable, being higher for the AHA/NHLBI and the 
NCEP-ATP III (Kappa 0.821) followed by the AHA/NHLBI 
and the IDF (Kappa 0.746) and the NCEP-ATP III and the 
IDF (Kappa 0.634). Global agreement (number of patients 
with MS according to all three definitions) was 45.3%. 
 There was a progressive increase on MS prevalence 
with age, from 40% in those with an age < 50 years, to 
54.1% in those between 50-59 years, 53.4% in those with 
60-69 years and 63.9% in those with 70 years or older. 
Overall, the prevalence was higher in the female gender 
(p=0.001) with different proportions according to age group. 
In younger patients, the prevalence was similar (40%), but 
after the fifth decade there is a divergence of prevalence 
between genders, with prevalence above 60% in women. 
In the age group of 50-59 years, the prevalence in males 
was 47.2% and in females 64.0%. In the age group of 60-69 
years, it was 42.9% and 68.5% and in the age group ≥ 70 
years, it was 55.1% and 76.5% respectively, in males and 
females.
 The most prevalent MS component by the AHA/NHLBI 
definition was hypertension, present in 85.7% of individuals, 
followed by abdominal obesity (58%), high blood glucose 
(53.7%), low HDL-cholesterol (48.3%) and elevated triglyc-
erides (22%) (Table 3). Atherogenic dislipidemia, defined 
by elevated triglycerides and/or low HDL-cholesterol, was 
present in 57% of individuals. We had an elevated percent-
age of patients with normal levels of triglycerides (78%) and 
HDL-cholesterol (51.7%). For the analysis of lipid profile, it 
is important to bare in mind that 60% of the present popula-
tion was under specific lipid-lowering therapy (56.6% with 
statins, 1.7% with fibrates and 1.7% with both). If consid-
ered the NCEP-ATP III definition, the prevalence of elevated 
glucose is lower than in the AHA/NHLBI definition (30.7%). 
In gender comparison, the main difference was found on 
abdominal obesity that was significantly higher in females 
(Table 4). With increasing age, we detected an increase in 
the prevalence of abdominal obesity, increased blood glu-
cose and low-HDL-cholesterol (Table 3). Elevated triglycer-
ides prevalence decreased slightly with age. No significant 
variation was detected for hypertension.
 Age was identical in the three BMI groups. MS preva-
lence, abdominal obesity, low HDL-cholesterol and in-
creased triglycerides were more prevalent in overweight 
and obese patients, with similar prevalence of hypertension 
and obesity (Table 5).
 Diabetes prevalence was also much higher with the new 
ADA definition compared with the 2003 definition (Table 2). 
The prevalence with the 2003 definition also increases with 
age, being 4% in those with an age < 50 years, to 21.3% 
in those between 50-59 years, 27.5% in those with 60-69 
years and 23% in those with 70 years or older. In diabet-
ics, the prevalence of MS was 65.2% (Males: 45% and 
Females: 93.1%) and 60.9% for abdominal obesity (Males: 
37.5% and Females: 93.1%). Diabetes was more prevalent 
in ‘Normal’ BMI group, followed by ‘Obese’ and ‘Overweight’ 
(Table 5).
 Significant angiographic coronary artery disease was 
present in 51.3% of patients, but it was significantly lower in 
females (35.8% vs. 62.1%, p<0.001). None of the MS defi-
nitions could predict the presence of significant coronary ar-
tery disease: NCEP-ATP III (OR 0.94, 95% CI 0.59 – 1.48, 
p=0.778), IDF (OR 0.89, 95% CI 0.56 – 1.42, p=0.629) and 
AHA/NHLBI (OR 0.98, 95% CI 0.62 – 1.55, p=0.935). The 
same was obtained after adjustment for age and gender: 
NCEP-ATP III (OR 1.24, 95% CI 0.75 – 2.05, p=0.397), IDF 
(OR 1.00, 95% CI 0.60 – 1.65, p=0.994) and AHA/NHLBI 
(OR 1.09, 95% CI 0.66 – 1.78, p=0.740).
DISCUSSION
 We found in our study population a very high prevalence 
of obesity compared to other studies performed in primary 
care setting. In our study group, 30% of the patients were 
obese, reaching an alarming value of 80% after inclusion 
of overweight patients, which is probably related to the fact 
that our population is a high-risk population. Obesity preva-
lence is particularly high in women, similar to previous stud-
ies. 
 Several epidemiological studies suggested an increase 
in MS prevalence in western societies as a consequence 
of the obesity epidemic particularly in the youngest.20,21 Fol-
lowing this increase in obesity, cardiovascular risk factors 
related with obesity (such as diabetes, hyperlipidemia and 
hypertension) are also more prevalent with an important 
impact in society.20 In a Portuguese study on the preva-
lence of obesity, it was reported an increase in obesity and 
overweight from the year 2003 to 2005, affecting already 
53.6% of the population.22 The IDEA study (International 
Day for the Evaluation of Abdominal Obesity) recently pub-
lished and conducted in 63 countries at primary care level, 
detected obesity in 24% of men and 27% of females and 
abdominal obesity in 29% and 48% respectively.23 In the 
Portuguese cohort, 25.5% were obese and 39.6% were 
overweight, with higher prevalence compared to previous 
studies and close to our results. These results might be ex-
plained by the fact that our population has a high cardiovas-
cular risk (with different characteristics from primary care) or 
might translate a real increase in obesity/overweight preva-
lence, as suggested by epidemiological studies in the last 
decades.
 In our sample, the prevalence of MS by the AHA/NHLBI 
definition was very high (48.4%) compared with previous 
studies. The prevalence was also different according to the 
definition used, being lower with the NCEP-ATP III definition 
(39.3%), followed by the AHA/NHLBI, and higher with the 
IDF definition (53.8%), confirming previous reports in which 
MS prevalence by the AHA/NHLBI definition is intermedi-
ate to the other two definitions. The higher prevalence with 
the IDF definition reflects the different abdominal obesity 
criteria as well as the fact that this is an obligatory com-
ponent. Other definitions do not give such an emphasis on 
Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                87
Table 2 – Metabolic syndrome (MS) and diabetes crude and adjusted prevalence.
(%)
MS
AHA/NHLBI
MS
NCEP-ATP III
MS
IDF
Diabetes
ADA 2003
Diabetes
ADA 2010
Males 46.9 36.2 56.5 22.6 45.2
Females 67.5 61.0 72.4 23.6 50.4
Total 55.3 46.3 63.0 23.0 47.3
Total Adjusted 48.4 39.3 53.8 14.8 36.4
Table 3 – Prevalence of each metabolic syndrome component according to age.
Age (years)
Metabolic 
syndrome
Hypertension
Abdominal 
obesity
Increased 
glucose
Increased 
triglycerides
Low 
HDL-cholesterol
< 50 40.0% 88.0% 48.0% 28.0% 32.0% 24.0%
50 - 59 54.1% 77.0% 55.7% 47.5% 24.6% 44.3%
60-69 53.4% 87.0% 53.4% 58.0% 21.4% 50.4%
≥70 63.9% 89.2% 69.9% 59.0% 18.1% 55.4%
Total 55.3% 85.7% 58.0% 53.7% 22.0% 48.3%
Table 4 - Prevalence of individual metabolic syndrome components by gender and prevalence of metabolic syndrome by age and gen-
der.
Prevalence Males Females
Hypertension 85.9% 85.4%
Abdominal obesity 38.4% 86.2%
Increased triglycerides 24.3% 18.7%
Low HDL-cholesterol 41.2% 58.5%
Increased glucose 56.5% 49.6%
Metabolic syndrome 
      Total 46.9% 67.5%
      < 50 years 40.0% 40.0%
      50 – 59 years 47.2% 64.0%
      60 – 69 years 42.9% 68.5%
      ≥ 70 years 55.1% 76.5%
Table 5 – Metabolic syndrome components according to BMI groups.
Normal Overweight Obese p-value
Age (years) 65 ± 10 64 ± 9 65 ± 9 0.525
Male gender (%) 65.6 62.7 48.3 0.047
Lipid-lowering treatment (%) 54.1 61.3 61.8 0.572
Diabetes (%) 27.9 19.3 25.8 0.307
Metabolic syndrome (%) 23.0 54.0 79.8 <0.001
MS components (%)
    Hypertension 78.7 86.7 88.8 0.198
    Increased glucose 41.0 58.0 55.1 0.076
    Abdominal obesity 24.6 51.3 91.2 <0.001
    Low HDL-cholesterol 29.5 47.3 62.9 <0.001
    Increased triglycerides 8.2 22.0 31.5 0.003
MS: metabolic syndrome.
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abdominal obesity, which is at the same level as the other 
components. The age and gender-adjusted prevalence (to 
allow comparison with previous epidemiological studies in 
the general population) is higher than previous national and 
international population studies, confirming the higher prev-
alence of MS in our high-risk population.9-17,24,25
 Several epidemiological studies detected some varia-
tion of MS prevalence worldwide, according to geographical 
area, gender and ethnical background, suggesting an im-
portant effect of genetic and environmental factors, reinforc-
ing the importance of regional studies.7,8 Most studies used 
the NCEP-ATP III definition and showed an elevated preva-
lence of MS in different regions of the world. In the United 
States of America, the NHANES III study (Third National 
Health and Nutrition Examination Survey), reported a global 
prevalence of 23.7%, increasing after 40 years of age and 
no differences were detected between genders.24 However, 
it detected a significant difference by ethnical origin, being 
more prevalent in Hispanic patients (31.9%) compared to 
Caucasians (23.8%) or Afro-American patients (21.6%). In 
the DECODE (Diabetes Epidemiology: Collaborative analy-
sis Of Diagnostic Criteria in Europe) study, conducted in 
Europe in non-diabetic patients and using the NCEP-ATP 
III criteria, MS prevalence was 25.9% in males and 23.4% 
in females, close to the NHANES III registry.26 Globally, 
smaller studies in Europe with the NCEP-ATP III definition 
reported prevalences close to 20-25%, but with significant 
geographical variations from 11.8% to 24.5% in Mediterra-
nean countries.25,27-35 However, comparisons between stud-
ies must be done with caution due to different definitions as 
well as with different population characteristics. 
 In Portugal some studies were performed at primary 
care level. A study by Santos, et al. in an urban population 
showed that 24% of the population fulfilled the NCEP-ATP 
III criteria for MS.11,16 However, this result cannot be gener-
alized to the general population with different characteristics 
from an urban population. The same author reported that 
the prevalence according to the NCEP-ATP III definition 
was 24.0%, 26.4% by the WHO definition, 37.2% by the 
AHA/NHLBI definition and 41.9% according to the IDF defi-
nition. The VALSIM (Estudo Epidemiológico de Prevalên-
cia da Síndrome Metabólica na População Portuguesa) 
study is the largest study on cardiovascular risk profile of an 
adult Portuguese population followed in primary care.21 MS 
prevalence in that study (by the NCEP-ATP III definition) 
was elevated (27.5% non-adjusted and 23.7% adjusted to 
age and gender), similar to the NHANES III report. In non-
diabetic patients, the prevalence was 27.6% (19.8% adjust-
ed), lower than in the DECODE study report. The VALSIM 
study also showed an important regional variation. That 
study used NCEP-ATP III MS definition and in our study, the 
prevalence was higher with both the AHA/NHLBI definition 
(our main definition) and NCEP-ATP III definition (p<0.001). 
Thus, our results showed a higher prevalence of MS even 
after age and gender adjustment, reflecting a high-risk pop-
ulation, but as in the case of obesity, it can also reflect a real 
increase in the prevalence of MS in the population, because 
previous studies were done before 2008 (Fig.1). 
 In general, good agreement was found between defini-
tions. The agreement was highest when we compared the 
AHA/NHLBI definition with the NCEP-ATP III definition, and 
lowest with the IDF definition. This reflects the fact that the 
first two definitions consider the same five factors to de-
scribe MS: central obesity, raised fasting glucose, raised tri-
glyceride levels, reduced HDL-cholesterol and raised blood 
pressure. Moreover, the AHA/NHLBI definition only makes 
minor changes to the NCEP-ATP III definition, lowering the 
threshold for considering raised fasting glucose. Also, the 
IDF and the AHA/NHLBI definitions include the use of phar-
macological treatment for the metabolic abnormalities, con-
sidering the component present when a subject takes that 
specific medication. However, our global agreement be-
tween definitions was only 45.3%, which was lower than the 
61% reported by Santos et al., but with similar results when 
comparing each pair of definitions.16 It is therefore very im-
portant to agree on a single definition. This is very important 
 
Fig. 1 – Prevalence of metabolic syndrome and each metabolic syndrome component in our study and compared to the VALSIM study.
* p-value < 0.001.
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not only to compare prevalence across populations but also 
to correctly identify cases with MS. 
 As expected, we found a significant association of age 
and female gender with MS prevalence, similar to the VAL-
SIM study.21 Overall, obesity is more prevalent in women 
with a prevalence above 60% in women above 50 years. 
Portuguese and Italian epidemiological studies showed 
an increased risk of MS in women, unlike other studies 
such as the NHANES III study where no difference was 
found.21,24,33,34,36 However, this last study also analysed dif-
ferent ethnic groups and concluded that there is a higher 
prevalence of MS amongst North American Caucasian men 
(24.8 vs. 22.8%) and amongst Afro-American and Hispanic 
females (25.7% vs. 16.4% and 35.6 vs. 28.3%, respective-
ly). This data suggests an important influence of ethnicity. In 
general, the prevalence of each component is higher than 
in primary care populations, reflecting the study high-risk 
population, with the exception of raised triglycerides that 
are less frequent and probably related to the fact that a 
very significant proportion of patients were on lipid lowering 
therapy. Comparing the prevalence of high blood glucose 
reported in the VALSIM study (with the NCEP-ATP III defini-
tion – 25.0%) with ours, using the same definition (30.7%), 
to allow a more accurate comparison, it was significantly 
higher (p=0.021), confirming that in this high-risk popula-
tion there is a poor glucose control. We also like to mention 
the fact that raised blood glucose was present in 53.7% of 
patients with the AHA/NLHBI definition, compared with the 
30.7% obtained with the NCEP-ATP III definition (p<0.001), 
as a result of the cut-off reduction of fasting blood glucose 
in the most recent MS definition. 
 In our population, the adjusted diabetes prevalence 
was 14.8%, close to the prevalence obtained in the 
VALSIM (13%) and the IDEA study in the general popula-
tion.16,23 No gender difference was detected. However, it is 
worth to mention that with the most recent diabetes defi-
nition from the ADA, which included glicated hemoglobin 
as a criterion, the adjusted prevalence in our population 
increases to 36.4%, which is a very significant increase. 
This will have an important impact in therapeutical terms, 
because it will imply an important increase in medical costs. 
As expected, the prevalence of diabetes is also highly age-
dependent, similar to the DECODE study.26
 We can conclude from these results that although dia-
betic patients are considered to have a high-risk for coro-
nary artery disease, they aren’t being consistently referred 
for coronary angiography. Diabetic patients are often as-
ymptomatic or present with atypical / equivalent symptoms, 
which might delay referral for coronary angiography. There-
fore, since the risk in these patients is very high, medical 
doctors should be more alert for signs suggestive of myo-
cardial ischemia with subsequent referral for coronary an-
giography in case of ischemia detection by non-invasive 
tests.
 Our study showed a surprisingly low diagnostic yield of 
coronary angiography. However, recent registries point to 
the same results. The recently published CathPCI Regis-
try of the National Cardiovascular Data Registry (NCDR), 
a large registry of clinical data and in-hospital outcome 
data associated with diagnostic cardiac catheterisation and 
percutaneous coronary interventions collected from more 
than 800 United States sites reported also a low diagnostic 
yield in patients without previously known coronary artery 
disease, with only a minority of patients with obstructive 
disease (41.0%) similar to our results.37 This registry repre-
sents contemporary clinical practice in the community.
 In our population, no association was found between 
MS (by any definition) and significant angiographic coronary 
artery disease. These results are in opposition to previous 
reports that showed an association between MS and car-
diovascular events.1 However, our study is an angiographic 
study that provides different information from that obtained 
in epidemiological studies that analyse cardiovascular 
events. Acute cardiovascular events have different patho-
physiological mechanisms from what we observe in stable 
coronary atherosclerotic plaque and metabolic syndrome 
seems to be more related with vulnerable atherosclerotic 
plaques. In fact,  the metabolic syndrome factors confer 
very different intensities of independent risk for angiograph-
ic coronary artery disease, from high independent risk of 
hypertriglyceridemia and high blood glucose to almost no 
independent effect of overweight that even appears to be 
protective.38 In the absence of obesity, three other higher 
risk criteria are required for the diagnosis. As a result, there 
is heterogeneity of risk among patients with metabolic syn-
drome, depending on the particular criteria used to diag-
nose it. 
CONCLUSIONS
 In this high-risk population of patients with suspected 
coronary artery disease, metabolic syndrome prevalence 
is high, with similar diabetes prevalence compared with 
general population epidemiological studies.  Metabolic 
syndrome prevalence is highest with the IDF definition, fol-
lowed by the AHA/NHLBI definition and the NCEP-ATP III 
definition. However, global agreement between definitions 
is modest, which might have implications in the results of 
studies on metabolic syndrome. There is an important age-
dependence of metabolic syndrome and diabetes preva-
lence. In women, the prevalence of metabolic syndrome is 
significantly higher, related with the very high prevalence of 
increased abdominal obesity.
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